[1]芦 嘉,史伟峰.血清miRNA-720和miRNA-484在结肠癌分期及早期诊断中的应用[J].现代检验医学杂志,2017,32(01):77-79,83.[doi:10.3969/j.issn.1671-7414.2017.01.021]
　LU Jia,SHI Wei-feng.Application of Serum miRNA-720 and miRNA-484 in the Staging and Early Diagnosis of Colon Cancer[J].Journal of Modern Laboratory Medicine,2017,32(01):77-79,83.[doi:10.3969/j.issn.1671-7414.2017.01.021]
点击复制

血清miRNA-720和miRNA-484在结肠癌分期及早期诊断中的应用()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年01期
页码:
77-79,83
栏目:
论著
出版日期:
2017-01-25

文章信息/Info

Title:
Application of Serum miRNA-720 and miRNA-484 in the Staging and Early Diagnosis of Colon Cancer
文章编号:
1671-7414(2017)01-077-04
作者:
芦 嘉; 史伟峰
常州市第一人民医院检验科,江苏常州 213003
Author(s):
LU Jia; SHI Wei-feng
Department of ClinicalLaboratory, the First People's Hospital of Changzhou City,Jiangsu Changzhou 213003,China
关键词:
结肠癌;  微小iRNA-720;  微小RNA-484;  生物标记
分类号:
R735.35; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.01.021
文献标志码:
A
摘要:
目的 探讨血清miRNA-720和miRNA-484是否能作为非侵入性的结肠癌生物标记。方法 采用实时荧光定量PCR检测104例结肠癌患者(分为Ⅰ～Ⅱ期组和Ⅲ～Ⅳ期组)以及60例健康对照血清中miRNA-720和miRNA-484的表达。通过ROC曲线分析两种miRNA对不同分期结肠癌患者的诊断价值。结果 与健康对照组相比,miRNA-720在Ⅰ～Ⅱ期组上调接近2倍(t=1.997,P＜0.05),在Ⅲ～Ⅳ期组上调3倍左右(t=2.133,P＜0.05); miRNA-484在Ⅰ～Ⅱ期组下调约2倍(t=2.585,P＜0.05),在Ⅲ～Ⅳ期组上调超过3倍(t=3.416,P＜0.01)。 两种miRNA用于诊断结肠癌的ROC曲线下面积(AUC)分别为0.76(95%CI:0.67～0.86)和0.79(95%CI:0.69～0.89); 两者联合使用可增至0.87(95%CI:0.77～0.96)。结论 血清miRNA-720和miRNA-484可作为非侵入性生物标记对结肠癌做出早期诊断,并能区别出不同分期的结肠癌。
Abstract:
Objective To investigate whether serum miRNA-720 and miRNA-484 can be used as non-invasive biomarkers of colon cancer.Methods Real time-polymerase chain reaction was used to detect the expressions of miRNA-720 and miRNA-484 in serum from 104 colon cancer patients(divided into Ⅰ～Ⅱ-stage group and Ⅲ～Ⅳ-stage group)compared with 60 additional healthy controls.ROC curve was performed to analyse the diagnosticusefulness of both miRNAs distinguishing between different stages of colon cancer patients.Results Compared with healthy controls,themiRNA-720 was upregulated close to 2 times in Ⅰ～Ⅱ-stage group(t=1.997,P＜0.05),and was upregulated about 3 times in Ⅲ～Ⅳ-stage group(t=2.133,P＜0.05).The miRNA-484 was downregulated almost 2 times in Ⅰ～Ⅱ-stagegroup(t=2.585,P＜0.05),but was upregulated over 3 times in Ⅲ～Ⅳ-stage group(t=3.416,P＜0.01).The area under the ROC curve(AUC)for the diagnosis of colon cancer were 0.76(95%CI:0.67～0.86)and 0.79(95%CI:0.69～0.89)respectively.The combined use of both miRNAs could make the AUC up to0.87(95%CI:0.77～0.96).Conclusion Serum miRNA-720and miRNA-484 can be used as non-invasive biomarkers to diagnose early colon cancer.They can also distinguish between different stages of colon cancer patients.

参考文献/References:

[1] Xiao ZG,Deng ZS,Zhang YD,et al.Clinical significance of microRNA-93 downregulation in human colon cancer[J].Eur J Gastroenterol Hepatol,2013,25(3):296-301.
[2] Hofsli E,Sjursen W,Prestvik WS,et al.Identification of serum microRNA profiles in colon cancer[J].Br J Cancer,2013,108(8):1712-1719.
[3] Li T,Leong MH,Harms B,et al.MicroRNA-21 as a potential colon and rectal cancer biomarker[J].World J Gastroenterol,2013,19(34):5615-5621.
[4] Chevillet JR,Lee I,Briggs HA,et al.Issues and prospects of microRNA-based biomarkers in blood and other body fluids[J].Molecules,2014,19(5):6080-6105.
[5] Kita Y,Vincent K,Natsugoe S,et al.Epigenetically regulated microRNAsand their prospect in cancer diagnosis[J].Expert Rev Mol Diagn,2014,14(6):673-683.
[6] McDonald MK,Capasso KE,Ajit SK.Purification and microRNA profil ing of exosomes derived from blood and culture media[J].J Vis Exp,2013(76):e50294.
[7] 李 琳,张连海,季加孚.外周血循环核酸作为肿瘤标志物在胃癌中的应用现状[J]. Li L,Zhang LH,Ji JF.Application status of circulating nucleic acids as biomarkers in gastric cancer[J].Chin J Gastrointest Surg,2014,17(1):21-25.
[8] Valencia K,Luis-Ravelo D,Bovy N,et al.miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization[J].Mol Oncol,2014,8(3):689-703.
[9] Ge QY,Zhou YX,Lu JF,et al.miRNA in plasma exosome is stable under different storage conditions[J].Molecules,2014,19(2):1568-1575.
[10] Ye JJ,Cao J.MicroRNAs in colorectal cancer as ma-rkers and targets:recent advances[J].World J Gastroenterol,2014,20(15):4288-4299.
[11] Hofsli E, Sjursen W, Prestvik WS,et al.Identification of serum microRNA profiles in colon cancer[J].Br J Cancer,2013,108(8):1712-1719.
[12] Nonaka R,Miyake Y,Hata T,et al.Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer[J].Int J Oncol,2015,47(3):1097-1102.
[13] Wang K,Long B,Jiao JQ,et al.miR-484 regulates mitochondrial network through targeting Fis1[J].Nat Commun,2012(3):781.
[14] Piepoli A,Tavano F,Copetti M,et al.Mirna expression profiles identify drivers in colorectal and pancreatic cancers[J].PLoS One,2012,7(3):e33663.
[15] 王钦君,张红春,申娴娟,等.MicroRNAs作为结直肠癌潜在标记物的研究进展[J].现代检验医学杂志,2015,30(4):107-110,114. Wang QJ,Zhang HC,Shen XJ,et al.MicroRNAs as a potential marker in the progress of colorectal cancer[J].Journal of Modern Laboratory Medicine,2015,30(4):107-110,114.

相似文献/References:

[1]吴 奇,申高飞,孙丽娜,等.miR-181d在结肠癌中表达失调并抑制癌细胞增殖及凋亡[J].现代检验医学杂志,2017,32(02):15.[doi:10.3969/j.issn.1671-7414.2017.02.004]
　WU Qi,SHEN Gao-fei,SUN Li-na,et al.miR-181d Inhibits Proliferation and Promotes Apoptosis in Colon Cancer Cells[J].Journal of Modern Laboratory Medicine,2017,32(01):15.[doi:10.3969/j.issn.1671-7414.2017.02.004]
[2]李 洪,唐 浏,郑 淋,等.结肠癌组织中microRNA-126表达及临床意义[J].现代检验医学杂志,2017,32(04):60.[doi:10.3969/j.issn.1671-7414.2017.04.017]
　LI Hong,TANG Liu,ZHENG Lin,et al.Expression of microRNA-126 in Colon Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(01):60.[doi:10.3969/j.issn.1671-7414.2017.04.017]

备注/Memo

备注/Memo:
作者简介:芦 嘉(1983-),男,学士,主管技师,主要从事临床生化检验,Tel:13813696921,E-mail:158585359@qq.com。
通讯作者:史伟峰,男,硕士,主任技师,研究方向为临床微生物耐药机制及耐药基因的研究,Tel:0519-68870895,E-mail:13961120249@163.com。
更新日期/Last Update: 2017-01-20